Skip to main content

Table 1 Summary of drugs identified as TRAIL sensitizing agents and their previously known activity.

From: Parallel screening of FDA-approved antineoplastic drugs for identifying sensitizers of TRAIL-induced apoptosis in cancer cells

10 μM
Drug Name Drug Alone Drug Alone + TRAIL Alone
(Additive)
Combination Treatment p-Value Known TRAIL Sensitizer? Known TRAIL Sensitizer in Prostate Cancer? Known TRAIL Sensitizer in Pancreatic Cancer?
Daunorubicin 47 51.3 95.6 < 0.01 Yes No No
Docetaxel 31.2 35.5 72.7 < 0.01 Yes Yes No
Doxorubicin 39 43.3 90.8 < 0.01 Yes Yes Yes
Epirubicin 34.7 39 58.7 < 0.05 Yes Yes No
Fludarabine 58.6 62.9 86.2 < 0.05 Yes No No
Idarubicin 53.3 57.6 97.7 < 0.01 No No No
Irinotecan 30.6 34.9 65.4 < 0.01 Yes Yes No
Mithramycin 28.6 32.9 95 < 0.01 Yes Yes No
Mitoxantrone 52.2 56.5 97.7 < 0.01 No No No
20 μM
Cladribine 0 4.1 38.5 < 0.05 No No No
Cytarabine 7.9 12.2 32.9 < 0.05 No No No
Gemcitabine 28.4 32.7 70.5 < 0.01 Yes Yes Yes
Thioguanine 4.7 9 40.8 < 0.05 No No No
Thiotepa 6.2 10.5 47.2 < 0.01 No No No
  1. Values are listed as mean percent viability reduction. Leads employed in an expanded dose response are shown in bold font.